Back to discover
Disease

Vaccinia

Late-stage therapeutic developmentEmerging research
MeSHVaccinia
1
Publications
7
Clinical trials
2000
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q3 2026.
Upcoming Milestones
Major developments
Upcoming trial readoutWorth watching
Evaluating the Durability of the Human Immune Response to the JYNNEOS Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine
Results expected Q3 20262025-10-16
Clinical Milestones1View
Results expected 1
Activity timeline1

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Tecovirimatapproved

Approval — Tecovirimat SIGA is indicated for the treatment of the following viral infections in adul… (2022)

Clinical trials

5 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
7
All trials
1
Active
2
Late-stage
5
Completed
Recently completed

Double-blind, Comparative, Randomized, Placebo-controlled Study on Immunogenicity, Reactogenicity and Safety of Live Cell-based Vaccine Against Smallpox and Other Orthopoxvirus Infections (VACΔ6 Vaccine) in Volunteers Aged 18-60 Years

Phase 2/3 · Completed · Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"

An Open, Simple, Randomized Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years in Parallel Groups

Phase 1 · Completed · Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"

An Open-label Controlled Study of the Safety and Tolerability of the Live Cell-based Vaccine Against Smallpox and Other Orthopoxvirus Infections (VAC∆6 Vaccine) Based on Vaccinia Virus, in Volunteers Aged 18-40 Years

Phase 1 · Completed · Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"

A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects

Phase 3 · Completed · Bavarian Nordic

Evaluation and Treatment of Ocular Complications of Vaccinia Vaccination: Suitability of NP-016 Vaccinia Immune Globulin (VIG) for Sight-Threatening Conditions [VIG31]

Phase 2 · Completed · National Eye Institute (NEI)

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2022emaApproval — Tecovirimat· Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13kg: Smallpox Cowpox Tecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13kg . Tecovirimat SIGA should be used in accordance with official recommendations. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice.

The Journal of experimental medicine · 2000 · 1,234 cites
Recent publications

Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice.

The Journal of experimental medicine · 2000 · 1,234 cites
Major themes1
  • Immunologic Memory1
Leading journals1
  • The Journal of experimental medicine1
Leading researchers8
  • Brasel K1
  • Brown SN1
  • Butz EA1
  • Charrier K1
  • Embers M1
  • Glaccum M1
  • Joyce S1
  • Kennedy MK1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

The cutaneous and occasional systemic reactions associated with vaccination using smallpox (variola) vaccine.

Identifiers
MeSHVaccinia
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.